Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AACR 2016 /
5 year survival rates for nivolumab-treated metastatic melanoma patients much higher than historical rates

16th - 20th Apr 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 06.05.16
Views: 1850
Rating:

Dr Stephen Hodi - Dana-Farber Cancer Institute, Boston, USA

Dr Stephen Hodi presents results at AACR 2016, following up on five year survival rates of metastatic melanoma patients who had received nivolumab.

He reports that the number of patients surviving beyond the five year mark is double that of treatment in years before nivolumab was available (34% v 16.6% 2005-2011)

For more on these results, you can read the associated news article here.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation